Display options
Cite
Cooiman MI, Alsters SIM, Duquesnoy M, et al. Long-Term Weight Outcome After Bariatric Surgery in Patients with Melanocortin-4 Receptor Gene Variants: a Case-Control Study of 105 Patients. Obes Surg. 2022;doi: 10.1007/s11695-021-05869-x.
Cooiman, M. I., Alsters, S. I. M., Duquesnoy, M., Hazebroek, E. J., Meijers-Heijboer, H. J., Chahal, H., Le Beyec-Le Bihan, J., Clément, K., Soula, H., Blakemore, A. I., Poitou, C., & van Haelst, M. M. (2022). Long-Term Weight Outcome After Bariatric Surgery in Patients with Melanocortin-4 Receptor Gene Variants: a Case-Control Study of 105 Patients. Obesity surgery, . https://doi.org/10.1007/s11695-021-05869-x
Cooiman, Mellody I, et al. "Long-Term Weight Outcome After Bariatric Surgery in Patients with Melanocortin-4 Receptor Gene Variants: a Case-Control Study of 105 Patients." Obesity surgery vol. (2022). doi: https://doi.org/10.1007/s11695-021-05869-x
Cooiman MI, Alsters SIM, Duquesnoy M, Hazebroek EJ, Meijers-Heijboer HJ, Chahal H, Le Beyec-Le Bihan J, Clément K, Soula H, Blakemore AI, Poitou C, van Haelst MM. Long-Term Weight Outcome After Bariatric Surgery in Patients with Melanocortin-4 Receptor Gene Variants: a Case-Control Study of 105 Patients. Obes Surg. 2022 Jan 04; doi: 10.1007/s11695-021-05869-x. Epub 2022 Jan 04. PMID: 34984630.
Copy Download .nbib Format: NLM
Share it on

Obes Surg. 2022 Jan 04; doi: 10.1007/s11695-021-05869-x. Epub 2022 Jan 04.

Long-Term Weight Outcome After Bariatric Surgery in Patients with Melanocortin-4 Receptor Gene Variants: a Case-Control Study of 105 Patients.

Obesity surgery

Mellody I Cooiman, Suzanne I M Alsters, Maeva Duquesnoy, Eric J Hazebroek, Hanne J Meijers-Heijboer, Harvinder Chahal, Johanne Le Beyec-Le Bihan, Karine Clément, Hedi Soula, Alex I Blakemore, Christine Poitou, Mieke M van Haelst

Affiliations

  1. Department of Bariatric Surgery, Rijnstate Hospital/Vitalys Clinic, Wagnerlaan 55, Arnhem, the Netherlands. [email protected].
  2. Department of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. [email protected].
  3. Department of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  4. Nutrition Department, Reference Center for Rare Diseases, Assistance Publique Hopitaux de Paris, Pitie-Salpetriere Hospital, Paris, France.
  5. Department of Bariatric Surgery, Rijnstate Hospital/Vitalys Clinic, Wagnerlaan 55, Arnhem, the Netherlands.
  6. Department of Clinical Genetics, Amsterdam UMC, University of Amsterdam, De Boelelaan 1117, Amsterdam, the Netherlands.
  7. Department of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK.
  8. Department of Biochemistry for Endocrinology and Oncology, Obesity and Dyslipidemia Genetics Unit, Assistance Publique-Hospitaux de Paris, Sorbonne Université, Pitie-Salpetriere Hospital, Paris, France.
  9. INSERM, Nutrition and Obesities, Systemic Approaches (NutriOmics) Research Unit, Sorbonne Université, Paris, France.
  10. Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
  11. Department of Life Sciences, Brunel University London, London, UK.
  12. Department of Clinical Genetics, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands. [email protected].
  13. Department of Clinical Genetics, Amsterdam UMC, University of Amsterdam, De Boelelaan 1117, Amsterdam, the Netherlands. [email protected].

PMID: 34984630 DOI: 10.1007/s11695-021-05869-x

Abstract

INTRODUCTION: Pathogenic heterozygous MC4R variants are associated with hyperphagia and variable degrees of obesity. Several research groups have reported short-term weight loss outcomes after bariatric surgery in a few patients with MC4R variants, but lack of longer-term data prevents evidence-based clinical decision-making.

MATERIALS AND METHODS: Bariatric surgery patients with heterozygous (likely) pathogenic MC4R variants, from three collaborating centers in the Netherlands, France, and the UK, were compared to matched controls (matched 2:1 for age, sex, preoperative BMI, surgical procedure, and diabetes mellitus, but without MC4R mutations). Weight loss and regain outcomes up to 6 years of follow-up were compared.

RESULTS: At 60 months of follow-up after RYGB, cases with MC4R variants showed weight regain with a mean of 12.8% (± 10.4 SD) total weight loss (TWL) from nadir, compared to 7.9% (± 10.5 SD) in the controls (p = 0.062). Among patients receiving SG, the cases with MC4R variants experienced inferior weight loss (22.6% TWL) during the first year of follow-up compared to the controls (29.9% TWL) (p = 0.010).

CONCLUSIONS: This multicenter study reveals inferior mid-term weight outcomes of cases with MC4R variants after SG, compared to RYGB. Since adequate weight loss outcomes were observed after RYGB, this procedure would appear to be an appropriate surgical approach for this group. However, the pattern of weight regain seen in cases with MC4R variants after both RYGB and SG highlights the need for pro-active lifelong management to prevent relapse, as well as careful expectation management.

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Keywords: Bariatric surgery; MC4R variant; Obesity; Obesity genetics

References

  1. Dogan K, Betzel B, Homan J, et al. Long-term effect of laparoscopic Roux-en-Y gastric bypass on diabetes mellitus, hypertension and dyslipidaemia in morbidly obese patients. Obes Surg. 2014;24:1835–42. https://doi.org/10.1007/s11695-014-1310-2 . - PubMed
  2. le Roux CW, Heneghan HM. Bariatric surgery for obesity. Med Clin N Am. 2018;108:165–82. https://doi.org/10.1016/j.mcna.2017.08.011 . - PubMed
  3. Felsenreich DM, Langer FB, Kefurt R, et al. Weight loss, weight regain and conversions to Roux-en-Y gastric bypass: 10 year results of laparoscopic sleeve gastrectomy. Surg Obes Relat Dis. 2016;12(9):1655–62. https://doi.org/10.1016/j.soard.2016.02.021 . - PubMed
  4. Lubrano-Berthelier C, Dubern B, Lacorte JM, et al. Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating. J Clin Endocrinol Metab. 2006;91(5):1811–8. https://doi.org/10.1210/jc.2005-1411 . - PubMed
  5. Larsen LH, Echwald SM, Sorensen TI, Andersen T, Wulff BS, Pedersen O. Prevalence of mutations and functional analyses of melanocortin 4 receptor variants identified among 750 men with juvenile-onset obesity. J Clin Endocrinol Metab. 2005;90(1):219–24. https://doi.org/10.1210/jc.2004-0497 . - PubMed
  6. Stutzmann F, Tan K, Vatin V, et al. Prevalence of melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees. Diabetes. 2008;57(9):2511–8. https://doi.org/10.2337/db08-0153 . - PubMed
  7. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Investig. 2000;106(2):253–62. https://doi.org/10.1172/JCI9238 . - PubMed
  8. Hatoum IJ, Stylopoulos N, Vanhoose AM, et al. Melanocortin-4 receptor signaling is required for weight loss after gastric bypass surgery. J Clin Endocrinol Metab. 2012;97(6):E1023–31. https://doi.org/10.1210/jc.2011-3432 . - PubMed
  9. Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O’Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin-4-receptor gene. N Engl J Med. 2003;348:1085–95. https://doi.org/10.1056/NEJMoa022050 . - PubMed
  10. Demiralp DO, Berberoglu M, Akar N. Melanocortin-4 receptor polymorphisms in Turkish pediatric obese patients. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2011;17(1):70–4. https://doi.org/10.1177/1076029609354330 . - PubMed
  11. van den Berg L, van Beekum O, Heutink P, et al. Melanocortin-4 receptor gene mutations in a Dutch cohort of obese children. Obesity. 2011;19(3):604–11. https://doi.org/10.1038/oby.2010.259 . - PubMed
  12. Hainerova I, Larsen LH, Holst B, et al. Melanocortin 4 receptor mutations in obese Czech children: studies of prevalence, phenotype development, weight reduction response, and functional analysis. J Clin Endocrinol Metab. 2007;92(9):3689–96. https://doi.org/10.1210/jc.2007-0352 . - PubMed
  13. Aslan YR, Ranadive SA, Ersoy BA, Rogers SJ, Lustig RH, Vaisse C. Bariatric surgery outcome in a patient with complete MC4R deficiency. Int J Obes. 2011;35(3):457–61. https://doi.org/10.1038/ijo.2010.168 . - PubMed
  14. Jelin EB, Daggag H, Speer AL, et al. Melanocortin-4 receptor signaling is not required for short-term weight loss after sleeve gastrectomy in pediatric patients. Int J Obes. 2016;40:550–3. https://doi.org/10.1038/ijo.2015.230 . - PubMed
  15. Censani M, Conroy R, Deng L, et al. Weight loss after bariatric surgery in morbidly obese adolescents with MC4R mutations. Obesity. 2014;22(1):225–31. https://doi.org/10.1002/oby.20511 . - PubMed
  16. Valette M, Poitou C, Le Beyec J, Bouillot JL, Clement K, Czernichow S. Melanocortin-4 receptor mutations and polymorphisms do not affect weight loss after bariatric surgery. PLoS ONE. 2012;7(11): e48221. https://doi.org/10.1371/journal.pone.0048221 . - PubMed
  17. Moore BS, Mirshahi UL, Yost EA, et al. Long-term weight-loss in gastric bypass patients carrying melanocortin 4 receptor variants. PLoS ONE. 2014;9(4): e93629. https://doi.org/10.1371/journal.pone.0093629 . - PubMed
  18. Elkhenini HF, New JP, Syed AA. Five-year outcome of bariatric surgery in a patient with melanocortin-4 receptor mutation. Clinical Obesity. 2014;4:121–4. https://doi.org/10.1111/cob.12051 . - PubMed
  19. Aslan YR, Campos GM, Calton MA, Evans DS, Merriman RB, Vaisse C. Weight loss after Roux-en-Y gastric bypass in obese patients heterozygous for MC4R mutations. Obes Surg. 2011;21:930–4. https://doi.org/10.1007/s11695-010-0295-8 . - PubMed
  20. Cooiman MI, Kleinendorst L, Aarts EO, et al. Genetic obesity and bariatric surgery outcome in 1014 patients with morbid obesity. Obes Surg. 2019. https://doi.org/10.1007/s11695-019-04184-w - PubMed
  21. Li Y, Zhang H, Tu Y, et al. Monogenic obesity mutations lead to less weight loss after bariatric surgery: a 6-year follow-up study. Obes Surg. 2019;29(4):1169–73. https://doi.org/10.1007/s11695-018-03623-4 . - PubMed
  22. Kleinendorst L, Massink MPG, Cooiman MI, et al. Genetic obesity: next-generation sequencing results of 1230 patients with obesity. J Med Genet. 2018;(0):1-9. https://doi.org/10.1136/jmedgenet-2018-105351 - PubMed
  23. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association of molecular pathology. Genet Med. 2015;17(5):405–24. https://doi.org/10.1038/gim.2015.30 . - PubMed
  24. Brethauer SA, Kim J, el Chaar M, et al. Standardized outcomes reporting in metabolic and bariatric surgery. Surg Obes Relat Dis. 2015;11(3):489–506. https://doi.org/10.1016/j.soard.2015.02.003 . - PubMed
  25. van de Laar AW, van Rijswijk AS, Kakar H, Bruin SC. Sensitivity and specificity of 50% excess weight loss (50% EWL) and twelve other bariatric criteria for weight loss success. Obes Surg. 2018. https://doi.org/10.1007/s11695-018-3173-4 . - PubMed
  26. Shoar S, Saber A. Long-term and midterm outcomes of laparoscopic sleeve gastrectomy versus Roux-en-Y gastric bypass: a systematic review and meta-analysis of comparative studies. Surg Obes Relat Dis. 2016; 00–00. Doi: https://doi.org/10.1016/j.soard.2016.08.011 - PubMed
  27. Karmali S, Brar B, Shi X, Sharma AM, de Gara C, Birch DW. Weight recidivism post-bariatric surgery: a systematic review. Obes Surg. 2013;23(11):1922–33. https://doi.org/10.1007/s11695-013-1070-4 . - PubMed
  28. Shantavasinkul PC, Omotosho P, Corsino L, Portenier D, Torquati A. Predictors of weight regain in patients who underwent Roux-en-Y gastric bypass surgery. Surg Obes Relat Dis. 2016;12(9):1640–5. https://doi.org/10.1016/j.soard.2016.08.028 . - PubMed
  29. Voorwinde V, Steenhuis IHM, Janssen IMC, Monpellier VM, Stralen van MM. Definitions of long-term weight regain and their associations with clinical outcome. Obes Surg. 2020;30:527–36. https://doi.org/10.1007/s11695-019-04210-x . - PubMed
  30. Homan J, Boerboom A, Aarts E, et al. A longer biliopancreatic limb in Roux-en Y gastric bypass improves weight loss in the first years after surgery: results of a randomized controlled trial. Obes Surg. 2018. https://doi.org/10.1007/s11695-018-342 . - PubMed
  31. Thereaux J, Corigliano N, Poitou C, Oppert J-M, Czernichow S, Bouillot J-L. Comparison of results after one year between sleeve gastrectomy and gastric bypass in patients with BMI≥50 kg/m - PubMed
  32. Thereaux J, Veyrie N, Bardsmisn C, et al. Similar postoperative safety between primary and revisional gastric bypass for failed gastric banding. JAMA Surg. 2014;149(8):780–6. https://doi.org/10.1001/jamasurg.2014.625 . - PubMed
  33. Dijkhorst PJ, Boerboom AB, Janssen IMC, et al. Failed sleeve gastrectomy: single anastomosis duodenoileal bypass or Roux-en-Y gastric bypass? A multicentre cohort study Obes Surg. 2018. https://doi.org/10.1007/s116965-018-3429-z . - PubMed
  34. Miras AD, Kamocka A, Tan T, et al. Long limb compared with standard limb Roux-en-Y gastric bypass for type 2 diabetes and obesity: the LONG LIMB RCT. Efficacy Mech Eval 2021;8(3). Doi: https://doi.org/10.3310/eme08030 - PubMed
  35. Saleh M, Cheruvu MS, Moorthy K, Ahmed AR. Laparoscopic sleeve gastrectomy using a synthetic bioabsorbable staple line reinforcement material: post-operative complications and 6 year outcomes. Ann Med Surg. 2016;10:83–7. https://doi.org/10.1016/j.amsu.2016.08.005 . - PubMed
  36. Aarts EO, Dogan K, Koehestanie P, Aufenacker ThJ, Janssen IMC, Berends FJ. Long-term results after laparoscopic adjustable gastric banding: a mean fourteen year follow-up study. Surgery for Obesity and Related Diseases. 2014. https://doi.org/10.1016/j.soard.2014.03.019 . - PubMed
  37. Allen RE, Hughes TD, Ng JL, et al. Mechanisms behind the immediate effects of Roux-en-Y gastric bypass surgery on type 2 diabetes. Theor Biol Med Model. 2013;10:45. https://doi.org/10.1186/1742-4682-10-45 . - PubMed
  38. Pucci A, Batterham RL. Mechanisms underlying the weight loss effects of RYGB and SG: similar, yet different. J Endocrinol Invest. 2019;42:117–28. https://doi.org/10.1007/s40618-018-0892-2 . - PubMed
  39. Wadden TA, Tronieri JS, Sugimoto D, et al. Liraglutide 3.0 mg and intensive behavioral therapy (BIT) for obesity in primary care: the SCALE IBT randomized controlled trial. Obesity 2020;28(3):529–536. Doi: https://doi.org/10.1002/oby.22726 . - PubMed
  40. Collet TH, Dubern B, Mokrosinski J, et al. Evaluation of a melanocortin-4 receptor (MC4R) agonist (setmelanotide) in MC4R deficiency. Mol Metab. 2017;6(10):1321–9. https://doi.org/10.1016/j.molmet.2017.06.015 . - PubMed
  41. Clement K, van den Akker E, Argente J, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trial. Lancet Diabetes&Endocrinology. 2020. https://doi.org/10.1016/S2213-8587(20)30364-8 . - PubMed

Publication Types